Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$APTY - APT Systems Continues Toward Goals in Preparation for Future Product Releases
Company Secures Equity Agreements for Development Completion of Charting Software
SAN FRANCISCO, CA -- (Marketwired) -- 03/22/17 -- APT Systems, Inc. (OTC PINK: APTY), a fully reporting company in the Fintech software sector, is pleased to announce that the Company has continued to further equity capital raising activities as the Company advances toward the release of its charting software as a precursor to the highly anticipated Intuitrader app.
Management has accepted investment capital toward the goal strategized to fund the completion of certain project developments with a combination of restricted Common shares and Preferred Series B shares.
Glenda Dowie, CEO, commented, "This is a fundamental step in our preparation to bring our trading software to market. We believe we are standing on the threshold of great developments, and anticipate that this tranche of investment capital will bolster development on our charting software establishing a surge in momentum at a time that could not be more pivotal."
The additional authorized shares are issued to empower the Company to entertain advantageous merger and acquisition possibilities, and opportunities to bring talent to the team. With majority shareholder approval, by written consent, for an amendment to its Articles of Incorporation, the resulting share structure adjustment increases the number of shares of common stock authorized from 350,000,000 to 750,000,000 and Preferred Shares from 10,000,000 to 100,000,000.
The Amendment became effective on March 10, 2017 following the filing of a Certificate of Amendment with the Secretary of State of the State of Delaware.
APT Systems continues to move forward on discussions with various parties for investments, joint venture partnerships and software acquisitions, while continuing to build upon the founder's vision of delivering modern tools to modern traders. Management has purposed to remain transparent, as the Company regards highly the value of its loyal shareholders and the importance of communication in building a strong and successful business.
About APT Systems, Inc.: APT is an acronym for Applied Proprietary Trading. The Management of APT Systems, Inc. works to deliver stock trading tools and its platform Intuitrader with a focus on handheld devices; while also strategically acquiring other compatible financial businesses which demonstrate strong growth potential.
$APTY - CEO Provides Shareholder Update on Recent Activities
SAN FRANCISCO, CA -- (Marketwired) -- 03/02/17 -- APT Systems, Inc. (OTC PINK: APTY), a fully reporting company in the FinTech software sector, is extremely happy with accomplishments early in the year and as a result, we want to provide an update on recent activities.
During the first few months of 2017, the Company filed its preliminary Schedule 14C filing as part of the next steps to complete an increase in common and preferred shares to help attract direct investment from accredited investors. The Company will utilize the new issue of preferred shares with a higher value to advance negotiations. To date, five letters of interest for direct investments into the Company were received and have put us well on our way to achieving our current funding goals. Management intends to use the net proceeds for working capital and general corporate purposes. The Company is also continuously exploring and analyzing strategic M&A opportunities and marketing partnerships that enhance our growth outlook for this year which would lead to earlier revenue generating capabilities.
APT Systems continues to build upon the founder's vision of delivering modern tools to modern traders. Insider ownership of roughly 54% aligns insider interests with those of public shareholders and reflects the Company's demonstrated commitment to building shareholder value.
About APT Systems, Inc.: APT is an acronym for Applied Proprietary Trading. The Management of APT Systems, Inc. works to deliver stock trading tools and its platform Intuitrader with a focus on handheld devices; while also strategically acquiring other compatible financial businesses which demonstrate strong growth potential.
$APTY - CEO Provides Shareholder Update on Recent Activities
SAN FRANCISCO, CA -- (Marketwired) -- 03/02/17 -- APT Systems, Inc. (OTC PINK: APTY), a fully reporting company in the FinTech software sector, is extremely happy with accomplishments early in the year and as a result, we want to provide an update on recent activities.
During the first few months of 2017, the Company filed its preliminary Schedule 14C filing as part of the next steps to complete an increase in common and preferred shares to help attract direct investment from accredited investors. The Company will utilize the new issue of preferred shares with a higher value to advance negotiations. To date, five letters of interest for direct investments into the Company were received and have put us well on our way to achieving our current funding goals. Management intends to use the net proceeds for working capital and general corporate purposes. The Company is also continuously exploring and analyzing strategic M&A opportunities and marketing partnerships that enhance our growth outlook for this year which would lead to earlier revenue generating capabilities.
APT Systems continues to build upon the founder's vision of delivering modern tools to modern traders. Insider ownership of roughly 54% aligns insider interests with those of public shareholders and reflects the Company's demonstrated commitment to building shareholder value.
About APT Systems, Inc.: APT is an acronym for Applied Proprietary Trading. The Management of APT Systems, Inc. works to deliver stock trading tools and its platform Intuitrader with a focus on handheld devices; while also strategically acquiring other compatible financial businesses which demonstrate strong growth potential.
$APTY - For Investors
We believe that the Company should provide timely corporate information to its investors in order to allow our shareholders to make well informed investment decisions related to our Company's stock. With this in mind, investors can expect the following from us:
•The Company shall disclose information on financial results every quarter. The announcement will be provided in a standardized manner for ease of past and current performance comparisons.
•The Company shall consistently deliver all information in a clear and unambiguous manner to both institutional and individual investors.
•Management recognizes the importance of corporate governance and the need to make continuous improvements to maximize profits for shareholders in the long term.
•We are implementing various innovative approaches from a diverse Advisory Board to stringent internal controls that will enable continual monitoring of our performance.
APT Systems, Inc. was incorporated in the State of Delaware on October 29, 2010 to engage in the creation of innovative stock trading platforms and visualization solutions for the financial markets. The Company is in the early development stage with modest revenues. We have an effective S-1 Registration Statement and Prospectus making the company a fully reporting entity registered with the United States Securities and Exchange Commission. Initially the company will publically trade on the OTC Bulletin Board managed by NASDAQ with a future goal of moving to a higher tier exchange. This is early stage investing and all of the associated risks are outlined in the Prospectus. We appreciate your consideration of our opportunity and links are provided for your convenience.
Shaping the Future of Trading - See Highlights
$APTY - For Investors
We believe that the Company should provide timely corporate information to its investors in order to allow our shareholders to make well informed investment decisions related to our Company's stock. With this in mind, investors can expect the following from us:
•The Company shall disclose information on financial results every quarter. The announcement will be provided in a standardized manner for ease of past and current performance comparisons.
•The Company shall consistently deliver all information in a clear and unambiguous manner to both institutional and individual investors.
•Management recognizes the importance of corporate governance and the need to make continuous improvements to maximize profits for shareholders in the long term.
•We are implementing various innovative approaches from a diverse Advisory Board to stringent internal controls that will enable continual monitoring of our performance.
APT Systems, Inc. was incorporated in the State of Delaware on October 29, 2010 to engage in the creation of innovative stock trading platforms and visualization solutions for the financial markets. The Company is in the early development stage with modest revenues. We have an effective S-1 Registration Statement and Prospectus making the company a fully reporting entity registered with the United States Securities and Exchange Commission. Initially the company will publically trade on the OTC Bulletin Board managed by NASDAQ with a future goal of moving to a higher tier exchange. This is early stage investing and all of the associated risks are outlined in the Prospectus. We appreciate your consideration of our opportunity and links are provided for your convenience.
Shaping the Future of Trading - See Highlights
$APTY News coming, this one is flying under the radar.
www.aptsystemsinc.com/index.php
Shaping the Future of Trading
Global market access and wireless communication is fueling unprecedented opportunity for traders and investors everywhere. Our company is focusing its talents on serving their needs. APT’s front line professionals are experienced traders and technology specialists, who have previously developed and published custom technical analysis indicators, extraordinary charting methodology and trading platforms for financial markets.
'APT' is an acronym for ‘Applied Proprietary Trading’ and we are concentrating on the management and pioneering of innovative stock research tools along with significant visualization solutions for fund management.
$APTY News coming, this one is flying under the radar.
www.aptsystemsinc.com/index.php
Shaping the Future of Trading
Global market access and wireless communication is fueling unprecedented opportunity for traders and investors everywhere. Our company is focusing its talents on serving their needs. APT’s front line professionals are experienced traders and technology specialists, who have previously developed and published custom technical analysis indicators, extraordinary charting methodology and trading platforms for financial markets.
'APT' is an acronym for ‘Applied Proprietary Trading’ and we are concentrating on the management and pioneering of innovative stock research tools along with significant visualization solutions for fund management.
DROPPIN LIKE A ROCK, sorry to those that are underwater, its gonna see .002's this week.
$VPRB $900k- $1M in Revenues – Expecting a Very Solid December Quarter Report
strong long-term growth is predicted. It is also expected that cannabis legalization will have a positive effect on this sector
$VPRB $900k- $1M in Revenues – Expecting a Very Solid December Quarter Report
http://globalsmallcaps.com/2017/03/13/2491/
We think investors will be pleased with the upcoming December quarter results. We expect a minimum of $900,00 of revenue to be reported, but will not be surprised to see revenues in the $1.0 million range. We expect to see healthy sales and marketing spending within the income statement, which is something investors should support as the prospects for VPR to exert dominance within this rapidly changing sector are significant.
The Company in its current form is a result of the purchase of the wholesale assets of Vapor Corp. We believe these assets were the most solid of the Vapor Corp. portfolio. The brands being acquired are highly valued within the retail channel and among consumers.
While the growth rate in the markets for e-cigarettes and vaping have slowed over the past year, strong long-term growth is predicted. It is also expected that cannabis legalization will have a positive effect on this sector
Its a SCAM, but you can pretend its not. I flipped it for a nice profit, but I aint gonna lie, TOTAL PUMP N DUMP
$VPRB $900k- $1M in Revenues – Expecting a Very Solid December Quarter Report
$VPRB $900k- $1M in Revenues – Expecting a Very Solid December Quarter Report
http://globalsmallcaps.com/2017/03/13/2491/
We think investors will be pleased with the upcoming December quarter results. We expect a minimum of $900,00 of revenue to be reported, but will not be surprised to see revenues in the $1.0 million range. We expect to see healthy sales and marketing spending within the income statement, which is something investors should support as the prospects for VPR to exert dominance within this rapidly changing sector are significant.
The Company in its current form is a result of the purchase of the wholesale assets of Vapor Corp. We believe these assets were the most solid of the Vapor Corp. portfolio. The brands being acquired are highly valued within the retail channel and among consumers.
While the growth rate in the markets for e-cigarettes and vaping have slowed over the past year, strong long-term growth is predicted. It is also expected that cannabis legalization will have a positive effect on this sector
.002 coming, PUMP N DUMP
$VPRB $900k- $1M in Revenues – Expecting a Very Solid December Quarter Report
http://globalsmallcaps.com/2017/03/13/2491/
We think investors will be pleased with the upcoming December quarter results. We expect a minimum of $900,00 of revenue to be reported, but will not be surprised to see revenues in the $1.0 million range. We expect to see healthy sales and marketing spending within the income statement, which is something investors should support as the prospects for VPR to exert dominance within this rapidly changing sector are significant.
The Company in its current form is a result of the purchase of the wholesale assets of Vapor Corp. We believe these assets were the most solid of the Vapor Corp. portfolio. The brands being acquired are highly valued within the retail channel and among consumers.
While the growth rate in the markets for e-cigarettes and vaping have slowed over the past year, strong long-term growth is predicted. It is also expected that cannabis legalization will have a positive effect on this sector
It'll close above .15pps today, then well head back higher next week. I'll be moving funds around for next week, once Sriracha Stixs launch, investors will be chasing it well into the .20-30's
Azam scam
WHAT HAPPENED TO THE VOLUME ??
8472 shares on this article, that's just 1 article about ( $SGMD )Sriracha Seasoning Stixs ??? smh, absolutely crazy how big this will be, no worries on share price, other then I need to add more on this pull back.
http://www.highsnobiety.com/2017/02/21/sriracha-stix/
8472 shares on this article, that's just 1 article about (SGMD) Sriracha Seasoning Stixs ??? smh, absolutely crazy how big this will be, no worries on share price, other then I need to add more on this pull back.
http://www.highsnobiety.com/2017/02/21/sriracha-stix/
8472 shares on this article, that's just 1 article about Sriracha Seasoning Stixs ??? smh, absolutely crazy how big this will be, no worries on share price, other then I need to add more on this pull back.
http://www.highsnobiety.com/2017/02/21/sriracha-stix/
$SGMD-When Huy Fong food which is the real Sriracha guys posted on their Facebook page it got 2000 likes and 600 comments and over 300 shares. Does anyone doubt what will happen when Sriracha sticks actually ship? I don't. Just search google for Sriracha Seasoning Stix. And be impressed ($$$$$$$$$$$$$$$$$$)
With all these articles it's no wonder this traded 10mm shares yesterday.
What a list. And the Sriracha product hasn't even shipped yet. Sriracha Seasoning Sticks will be a culinary cult hit just like Sriracha sauce.
https://www.facebook.com/huyfongofficial/?hc_ref=SEARCH&fref=nf
http://www.highsnobiety.com/2017/02/21/sriracha-stix/
http://coolmaterial.com/food-drink/sriracha-seasoning-sticks/
http://www.blessthisstuff.com/stuff/culture/food/sriracha-seasoning-stix/
http://www.refinery29.com/2017/02/141156/stiiracha-seasoning-stix
http://www.popsugar.com/food/Sriracha-Seasoning-Stix-43182340
http://www.msn.com/en-us/foodanddrink/foodnews/these-sriracha-seasoning-sticks-will-change-the-way-you-cook/ar-AAnb5ey
http://www.dudeiwantthat.com/food/sriracha-seasoning-stix.asp
https://www.simplemost.com/sriracha-seasoning-sticks-meat-kitchen/
http://www.likecool.com/Sriracha_Seasoning_Stix--Gadget--Gear.html
http://dish.allrecipes.com/sriracha-stix/
http://www.travelandleisure.com/syndication/sriracha-seasoning-stix
http://www.thatsnerdalicious.com/spicy-foods/sriracha-seasoning-stix/
http://www.meatpoultry.com/articles/news_home/Business/2016/10/Sugarmade_unveils_Sriracha_Sea.aspx?ID=%7B49A541C5-37C8-439F-BB12-5FF0E2973F98%7D&cck=1
http://www.wideopeneats.com/sriracha-stix-are-here-and-we-cant-wait-to-try-them/
$SGMD-When Huy Fong food which is the real Sriracha guys posted on their Facebook page it got 2000 likes and 600 comments and over 300 shares. Does anyone doubt what will happen when Sriracha sticks actually ship? I don't. Just search google for Sriracha Seasoning Stix. And be impressed ($$$$$$$$$$$$$$$$$$)
With all these articles it's no wonder this traded 10mm shares yesterday.
What a list. And the Sriracha product hasn't even shipped yet. Sriracha Seasoning Sticks will be a culinary cult hit just like Sriracha sauce.
https://www.facebook.com/huyfongofficial/?hc_ref=SEARCH&fref=nf
http://www.highsnobiety.com/2017/02/21/sriracha-stix/
http://coolmaterial.com/food-drink/sriracha-seasoning-sticks/
http://www.blessthisstuff.com/stuff/culture/food/sriracha-seasoning-stix/
http://www.refinery29.com/2017/02/141156/stiiracha-seasoning-stix
http://www.popsugar.com/food/Sriracha-Seasoning-Stix-43182340
http://www.msn.com/en-us/foodanddrink/foodnews/these-sriracha-seasoning-sticks-will-change-the-way-you-cook/ar-AAnb5ey
http://www.dudeiwantthat.com/food/sriracha-seasoning-stix.asp
https://www.simplemost.com/sriracha-seasoning-sticks-meat-kitchen/
http://www.likecool.com/Sriracha_Seasoning_Stix--Gadget--Gear.html
http://dish.allrecipes.com/sriracha-stix/
http://www.travelandleisure.com/syndication/sriracha-seasoning-stix
http://www.thatsnerdalicious.com/spicy-foods/sriracha-seasoning-stix/
http://www.meatpoultry.com/articles/news_home/Business/2016/10/Sugarmade_unveils_Sriracha_Sea.aspx?ID=%7B49A541C5-37C8-439F-BB12-5FF0E2973F98%7D&cck=1
http://www.wideopeneats.com/sriracha-stix-are-here-and-we-cant-wait-to-try-them/
Ouch, not looking good today
$NPHC is hitting radars, its only a matter of time before this takes off.
http://globalsmallcaps.com/2017/02/14/nutra-pharma-corp/
Summary of Our Research Findings
•We begin coverage of Nutra Pharma, Corp. with a Buy recommendation and a price target of $0.10 per share.
•Nutra Pharma is in the process of introducing cobra toxin-based therapies for human and pet pain management markets and additionally has therapeutic drug development opportunities relative to HIV and MS.
•OTC sales are being driven by retail expansion and DRTV programs.
•The worldwide pain management market is of significant size and is undergoing dramatic change as physicians significantly curtail narcotic prescriptions. This is creating new opportunities for innovative pain treatment therapies and products. There is much focus on this sector.
•The Company was recently featured in NBC news. The interview is here: www.tinyurl.com/nyloxinNBC
•While we do not believe it to be the near term market opportunity for the Company, it also has a strong pipeline of possible therapies for autoimmune diseases and HIV. Orphan drug status as been granted for RPI-78M.
•In our opinion, this is an innovative company with a therapy that is exciting and could capture the imagination of risk-averse investors, yielding a significantly higher, stock price.
$NPHC is hitting radars, its only a matter of time before this takes off.
http://globalsmallcaps.com/2017/02/14/nutra-pharma-corp/
Summary of Our Research Findings
•We begin coverage of Nutra Pharma, Corp. with a Buy recommendation and a price target of $0.10 per share.
•Nutra Pharma is in the process of introducing cobra toxin-based therapies for human and pet pain management markets and additionally has therapeutic drug development opportunities relative to HIV and MS.
•OTC sales are being driven by retail expansion and DRTV programs.
•The worldwide pain management market is of significant size and is undergoing dramatic change as physicians significantly curtail narcotic prescriptions. This is creating new opportunities for innovative pain treatment therapies and products. There is much focus on this sector.
•The Company was recently featured in NBC news. The interview is here: www.tinyurl.com/nyloxinNBC
•While we do not believe it to be the near term market opportunity for the Company, it also has a strong pipeline of possible therapies for autoimmune diseases and HIV. Orphan drug status as been granted for RPI-78M.
•In our opinion, this is an innovative company with a therapy that is exciting and could capture the imagination of risk-averse investors, yielding a significantly higher, stock price.
NPHC is hitting radars, its only a matter of time before this takes off.
http://globalsmallcaps.com/2017/02/14/nutra-pharma-corp/
Summary of Our Research Findings
•We begin coverage of Nutra Pharma, Corp. with a Buy recommendation and a price target of $0.10 per share.
•Nutra Pharma is in the process of introducing cobra toxin-based therapies for human and pet pain management markets and additionally has therapeutic drug development opportunities relative to HIV and MS.
•OTC sales are being driven by retail expansion and DRTV programs.
•The worldwide pain management market is of significant size and is undergoing dramatic change as physicians significantly curtail narcotic prescriptions. This is creating new opportunities for innovative pain treatment therapies and products. There is much focus on this sector.
•The Company was recently featured in NBC news. The interview is here: www.tinyurl.com/nyloxinNBC
•While we do not believe it to be the near term market opportunity for the Company, it also has a strong pipeline of possible therapies for autoimmune diseases and HIV. Orphan drug status as been granted for RPI-78M.
•In our opinion, this is an innovative company with a therapy that is exciting and could capture the imagination of risk-averse investors, yielding a significantly higher, stock price.
$SGMD is a 100% BUY after this mornings selloff, with Sriracha Seasoning Stixs launching EOM and its Patented MJ Technology as well as its $5 Million in Revenues and Zero Toxic debt and Low Float, its a BUY BUY BUY!
$SGMD is a 100% BUY after this mornings selloff, with Sriracha Seasoning Stixs launching EOM and its Patented MJ Technology as well as its $5 Million in Revenues and Zero Toxic debt and Low Float, its a BUY BUY BUY!
lmao, I wasn't planning on averaging down, but I did this morning. Thanks to whomever sold, you probably don't have a real understanding on the company SUGARMADE or its Product Sriracha Seasoning Stixs or it's Patented Technology.
SGMD is different then 99% of OTC's, in the simplest way of saying it "THEY ARE A REAL COMPANY" with $5 Million in Revenues, Zero Toxic Debt and a very Low Float.
Thank you for the shares, we'll see new highs very soon.
Protect profits, congrats to all.
Good to see investors make some profits, congrats to all.
$NPHC Update- •We begin coverage of Nutra Pharma, Corp. with a Buy recommendation and a price target of $0.10 per share.
•Nutra Pharma is in the process of introducing cobra toxin-based therapies for human and pet pain management markets and additionally has therapeutic drug development opportunities relative to HIV and MS.
•OTC sales are being driven by retail expansion and DRTV programs.
•The worldwide pain management market is of significant size and is undergoing dramatic change as physicians significantly curtail narcotic prescriptions. This is creating new opportunities for innovative pain treatment therapies and products. There is much focus on this sector.
•The Company was recently featured in NBC news. The interview is here: www.tinyurl.com/nyloxinNBC
•While we do not believe it to be the near term market opportunity for the Company, it also has a strong pipeline of possible therapies for autoimmune diseases and HIV. Orphan drug status as been granted for RPI-78M.
•In our opinion, this is an innovative company with a therapy that is exciting and could capture the imagination of risk-averse investors, yielding a significantly higher, stock price.
$NPHC Update- •We begin coverage of Nutra Pharma, Corp. with a Buy recommendation and a price target of $0.10 per share.
•Nutra Pharma is in the process of introducing cobra toxin-based therapies for human and pet pain management markets and additionally has therapeutic drug development opportunities relative to HIV and MS.
•OTC sales are being driven by retail expansion and DRTV programs.
•The worldwide pain management market is of significant size and is undergoing dramatic change as physicians significantly curtail narcotic prescriptions. This is creating new opportunities for innovative pain treatment therapies and products. There is much focus on this sector.
•The Company was recently featured in NBC news. The interview is here: www.tinyurl.com/nyloxinNBC
•While we do not believe it to be the near term market opportunity for the Company, it also has a strong pipeline of possible therapies for autoimmune diseases and HIV. Orphan drug status as been granted for RPI-78M.
•In our opinion, this is an innovative company with a therapy that is exciting and could capture the imagination of risk-averse investors, yielding a significantly higher, stock price.
We need volume?
Did Ed die ?
This kinda died, any update from company as to why there is ZERO volume ??
Kinda dead around here ??????
$NPHC Analyst Coverage. CORAL SPRINGS, FL--(Marketwired - Feb 22, 2017) - Nutra Pharma Corporation ( OTCQB : NPHC ), a biotechnology company developing drugs for the treatment of Multiple Sclerosis and HIV that also markets Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that Global Small Caps has initiated coverage of the Company including operations and overall shareholder value.
The report is available at: http://tinyurl.com/NPHCreport
https://finance.yahoo.com/news/global-small-caps-initiates-coverage-133000273.html
$NPHC Analyst Coverage. CORAL SPRINGS, FL--(Marketwired - Feb 22, 2017) - Nutra Pharma Corporation ( OTCQB : NPHC ), a biotechnology company developing drugs for the treatment of Multiple Sclerosis and HIV that also markets Nyloxin® and Pet Pain-Away™ in the over-the-counter (OTC) pain management market, announced today that Global Small Caps has initiated coverage of the Company including operations and overall shareholder value.
The report is available at: http://tinyurl.com/NPHCreport
https://finance.yahoo.com/news/global-small-caps-initiates-coverage-133000273.html